Antibiotic-resistant bacteria can survive treatment through a surprisingly broad range of biological strategies.

New research involving laboratory experiments, genetic analysis, and patient monitoring has provided a closer look at how these organisms adjust to antibiotics and how resistant bacteria can become linked to serious infections in vulnerable patients.

Resistance Can Come With an Evolutionary Trade-Off

One investigation focused on carbapenem-resistant Klebsiella pneumoniae, a bacterium capable of developing resistance to multiple antibiotics. Researchers used a technique called high-density transposon sequencing, or TnSeq, to examine genes involved in antibiotic susceptibility. The approach allowed scientists to identify genetic changes that influence how the bacteria respond to antimicrobial drugs.

The findings revealed an important trade-off. Some bacteria can modify structures on their outer surface to avoid attack from bacteriophages, viruses that infect bacteria. However, losing or changing those surface receptors can make the bacteria more susceptible to certain last-line antibiotics.

The effect was observed with drugs including meropenem, colistin, and cefiderocol. In other words, a bacterial adaptation that provides protection against one threat may simultaneously create a weakness against another. This type of trade-off is important because bacterial resistance is not necessarily a simple process in which an organism becomes resistant to every treatment at once. Different survival strategies can affect one another, potentially creating opportunities for researchers to identify vulnerabilities.

How Bacteria Resist Cefiderocol

A second study examined cefiderocol, an antibiotic designed to take advantage of bacterial iron-uptake systems. Cefiderocol uses these pathways as an entry route into bacteria. Once inside, the drug can interfere with processes needed for bacterial survival. However, some strains of Klebsiella pneumoniae have developed mechanisms that reduce the drug's effectiveness.

The study found that removing blaKPC-3 from resistant strains reduced the minimum inhibitory concentration of the drug by fourfold. This result indicates that even relatively modest enzyme activity can contribute substantially to resistance when the amount of antibiotic reaching the bacterial interior is limited. The finding highlights why antibiotic resistance can involve several biological processes working together rather than a single mutation or mechanism.

Colonization Can Precede a Serious Bloodstream Infection

The third investigation moved from laboratory-based resistance mechanisms to clinical monitoring. Researchers followed 159 patients with acute leukemia or myelodysplastic syndrome who were receiving induction chemotherapy. The treatment can cause neutropenia, a condition involving very low levels of infection-fighting neutrophils.

Stool or perianal samples were examined for antibiotic-resistant Enterobacterales. Among the 159 participants, 15 were colonized with extended-spectrum beta-lactamase-producing Enterobacterales, known as ESBL-E. Another 17 were colonized with AmpC-producing Enterobacterales.

Three of the 15 patients carrying ESBL-E later developed bloodstream infections caused by ESBL-E during neutropenia. That represented 20% of the colonized group, compared with one patient among 144 participants without ESBL-E colonization.

Whole-genome sequencing provided another important detail. In each of the three ESBL-E bloodstream infections, the bacterial strain found in the blood was genetically identical to the strain previously identified during colonization. These findings suggest that screening for resistant bacteria before or during intensive treatment could provide useful information when clinicians select empirical antibiotic therapy for patients who develop suspected infections.

Expert Insight

Barry N. Kreiswirth, Ph.D., a member of the Hackensack Meridian Center for Discovery and Innovation and professor at Hackensack Meridian School of Medicine, emphasized the broader significance of the research. “These studies collectively show how we are tracking and better understanding the many forms of drug resistance that bacterial pathogens evolve, given the opportunity,” Kreiswirth said.

Why These Findings Matter

The studies provide several useful insights into antimicrobial resistance. First, bacterial adaptations can have consequences beyond the original survival advantage. A change that helps a bacterium avoid bacteriophages, for example, may simultaneously restore sensitivity to certain antibiotics.

Second, resistance to a newer antibiotic such as cefiderocol can depend on multiple interacting systems. Understanding those systems may help researchers identify weaknesses that could eventually be targeted in future treatments. Third, bacterial colonization can provide clinically relevant information. The patient study showed a clear connection between ESBL-E colonization and subsequent ESBL-E bloodstream infection within the specific population studied.

Together, the findings reinforce the value of combining genetic research, antimicrobial testing, genomic sequencing, and clinical surveillance. A clearer understanding of how bacteria adapt and how colonization relates to infection could help improve antibiotic selection and support more targeted approaches to treating resistant infections.